Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 16;6(9):2273–2285. doi: 10.1002/hep4.1993

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Changes in liver stiffness and hepatic fibrosis markers. (A) Magnetic resonance elastography liver stiffness measurements (MRE‐LSM) changes compared between baseline and tofogliflozin monotherapy, pioglitazone monotherapy, and combination therapy of tofogliflozin and pioglitazone. (B) Change in MRE‐LSM after 24 weeks and 48 weeks of monotherapy, and combination therapy, listed by initial monotherapy. (C) Wisteria floribunda agglutinin–positive Mac‐2 binding protein (WFA + −M2BP) changes compared between baseline and tofogliflozin monotherapy, pioglitazone monotherapy, and combination therapy of tofogliflozin and pioglitazone. (D) Type IV collagen 7S changes compared between baseline and tofogliflozin monotherapy, pioglitazone monotherapy, and combination of tofogliflozin and pioglitazone